Notice of Personal Information Transfer upon Merger
A merger agreement under which Celltrion, Inc. (“Celltrion”) as the surviving entity shall merge with Celltrion Healthcare Co., Ltd. (the “Company”) as the disappearing (merged) entity has been approved at the general meeting of shareholders held on October 23, 2023. Accordingly, Celltrion is scheduled to merge with the Company (the “Merger”) as of December 28, 2023 (the “Merger Date”).
Due to the Merger, the personal information of the Company’s customers and counterparties to transactions, as well as that of the Company’s officers and employees, which has been kept under the custody of the Company, will be transferred to Celltrion on the Merger Date (provided, the Merger Date and the date of personal information transfer may be changed or postponed, in which case the Company will further inform you of the changed transfer date).
Celltrion as the surviving entity will safely manage the personal information transferred from the Company pursuant to the Personal Information Protection Act and other applicable laws, and will use and process such information only to the extent consented, in the same manner as the Company has done to date.
The information of the surviving company to which the personal information will be transferred is as follows:
- Celltrion, Inc.
- Address : (Songdo-dong) 23, Academy-ro, Yeonsu-gu, Incheon, Republic of Korea
- Tel. : (+82) 1661-8722
- Email : investor@celltrion.com
If you do not consent to the transfer of your personal information as stated above, please contact the following person in charge of the matter for the Company. Even if you do not consent to the transfer of your personal information, the Company may retain part of your personal information for a certain period to comply with its obligations under applicable laws:
- Name : Jeong Kim
- Department/ Title : Compliance Support Team / Manager
- Tel. : (+82) 032-850-6938
- Email : DPO.CTHC@celltrionhc.com
We appreciate your cooperation and wish you a good health and prosperity.
November 20, 2023
Celltrion Healthcare Co., Ltd
4th Fl, 19, Academy-ro 51beon-gil, Yeonsu-gu, Incheon, Republic of Korea
Representative Director, Hyoung Ki Kim
Celltrion Healthcare
We have been contributing to the improvement of patient welfare and access to healthcare by offering innovative biologics to the world.
BUSINESSWe are exerting efforts to achieve sustainable growth.
Celltrion Healthcare will shape a healthier and happier future for humanity by offering high-quality biologics.
Celltrion Healthcare offers biologics to about 110 countries, along with more than 30 global partners around the world. With hands-on experience and knowledge accumulated through years of working in the advanced pharmaceutical markets of the United States and Europe, Celltrion Healthcare has been securing distribution channels and providing patients with biosimilars at affordable prices.
PRODUCTS
Remsima®
Remsima® is a biosimilar infliximab approved by the European Medicines Agency (EMA) in August 2013 and the U.S. Food and Drug Administration (FDA) in April 2016. It is indicated for the treatment of Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), and Psoriasis.
The world’s first biosimilar
monoclonal antibody
PRODUCTS
Truxima®
Truxima® is a biosimilar rituximab approved by the European Medicines Agency (EMA) in February 2017 and the U.S. Food and Drug Administration (FDA) in November 2018. It is indicated for the treatment of Non-Hodgkin's Lymphoma(NHL), Chronic Lymphocytic Leukemia(CLL), and Rheumatoid Arthritis(RA).
The world’s first biosimilar
anticancer antibody
PRODUCTS
Herzuma®
Herzuma® is a biosimilar trastuzumab approved by the European Medicines Agency (EMA) in February 2018 and the U.S. Food and Drug Administration (FDA) in December 2018. It is indicated for the treatment of HER2-Positive Metastatic Breast Cancer, Early Breast Cancer(EBC), and Metastatic Gastric Cancer(MGC).
Biosimilar anticancer antibody
PRODUCTS
Remsima®SC
Remsima®SC is a SC formulation of biosimilar infliximab approved by the European Medicines Agency (EMA) in November 2019. It is indicated for the treatment of Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients.
The world's first subcutaneous
infliximab biosimilar
-
Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs
더 알아보기
-
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease
더 알아보기
-
Data Presented at UEG Week 2023 Further Support the Potential of Celltrion’s Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease
더 알아보기
-
Celltrion USA has signed a contract with Ventegra® to add Yuflyma® (adalimumab-aaty) as a preferred formulary product in both public and private insurance markets
더 알아보기
GLOBAL NETWORKS
Global biologics
leading company
Celltrion Healthcare has become the world’s leading company that specializes in biologics by offering high-quality biosimilars to about 110 countries, with the ultimate goal of promoting the welfare of humanity.
